447
Participants
Start Date
August 31, 2012
Primary Completion Date
December 31, 2014
Study Completion Date
December 31, 2014
HP-802-247
HP802-247 (fibrinogen solution \& thrombin solution containing living, irradiated, growth arrested keratinocytes and fibroblasts) 260 µL (130 µL, one spray, of each solution) containing 0.5 x 106 cells per mL every 14 days.
Vehicle
(fibrinogen solution \& thrombin solution without cells)
New York
Dunmore
Wyomissing
Washington D.C.
Baltimore
Roanoke
Chapel Hill
Gainesville
Hialeah
Miami
South Miami
Tamarac
Akron
North Chicago
Chicago
Chicago
Chicago
Jacksonville
Springfield
Tulsa
Dallas
Fort Worth
Fort Worth
San Antonio
St. George
Phoenix
Phoenix
Glendale
Tucson
Tucson
Las Vegas
Los Angeles
Long Beach
Sylmar
Carlsbad
San Diego
Laguna Hills
Fresno
San Francisco
Castro Valley
Stockton
Tacoma
Boston
Cambridge
Emerson
Vancovuer
Greater Sudbury
Hamilton
London
Sherbrooke
Lead Sponsor
Smith & Nephew, Inc.
INDUSTRY
Healthpoint
INDUSTRY